The Physicians Really Are Healing Themselves, With Ozempic
1 day ago · Then he started taking Ozempic, the Novo Nordisk diabetes drug that is sold under the name Wegovy for obesity. He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo outlines new late-stage study of obesity drug CagriSema
Feb 5, 2025 · Dive Brief: Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test different doses and longer duration of treatment, the company said Wednesday.; The announcement comes six weeks after the Denmark-based company released data from another Phase 3 trial that underperformed executives’ expectations on …
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk defends next-gen obesity drug CagriSema, details …
6 days ago · In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...
Novo Nordisk hails ‘remarkable’ weight loss result for dual …
Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential...
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss …
Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.
Novo Nordisk readies trial results for next-generation weight-loss drug
Nov 17, 2024 · Novo Nordisk is preparing to unveil data for a “next generation” weight-loss drug it believes could lead the field of GLP-1 treatments, as drugmakers seek to better the results of blockbuster...
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo Nordisk …
Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same class as the blockbuster obesity and diabetes medications, Ozempic and Mounjaro.
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
2 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.